Peter Kastl, MD
Ophthalmology · New Orleans, LANPI 1467568055
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $30,102 of the $31,676 with a category attached, or 95.0%. CSL Plasma Inc. accounts for 95.0% of it on its own, with 11 other manufacturers making up the rest. Among ophthalmology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 73 payments — averaging $433.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Plasma Inc.$30K
- Glaukos Corporation$715
- Alcon$166
- Bausch & Lomb, A Division Of Bausch Health US, LLC$161
- Novartis$146
- Mallinckrodt Hospital Products Inc.$128
- plus $257 from 6 others
What the payments were for
- Consulting fees$30,10295%
- Food & beverage$1,5445%
- Gifts$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Plasma Inc. | 47 | $30,102 |
| Glaukos Corporation | 9 | $715 |
| Alcon | 3 | $166 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $161 |
| Novartis | 2 | $146 |
| Mallinckrodt Hospital Products Inc. | 1 | $128 |
| Amgen | 1 | $117 |
| Rayner Intraocular Lenses Limited | 2 | $41 |
| Bausch & Lomb Americas Inc. | 2 | $38 |
| Merz North America, Inc. | 1 | $30 |
| AbbVie | 1 | $16 |
| ANI Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$31,676 in reported general payments places this provider in the 95th percentile of 286 ophthalmology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RocklatanNetarsudil Mesylat/Latanoprost | 13 | $6,341 |
| Latanoprost | 156 | $1,034 |
| Prednisolone Acetate | 22 | $974 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 55 | $748 |
| Timolol Maleate | 26 | $173 |
| Brimonidine Tartrate | 26 | $137 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in New Orleans
- Rebecca MetzingerNew Orleans$63K
- Ze ZhangNew Orleans$44K
- Benjamin LeeNew Orleans$7K
- Glen CangelosiNew Orleans$6K
- Matthew BoltonNew Orleans$5K
- Barry LeaderNew Orleans$5K
- Blake WilliamsonBaton Rouge$443K
- Wyche ColemanShreveport$35K
- Bryan VekoviusShreveport$29K
- Christopher ShelbyShreveport$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.